We are live on
!
Find out more
JHC
Jones Hill Capital Portfolio holdings
AUM
$470M
This Fund
S&P 500
This Quarter
Est. Return
+9.39%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$470M
AUM Growth
+$3.89M
(+0.83%)
Cap. Flow
-$35.1M
Cap. Flow
% of AUM
-7.45%
Top 10 Holdings %
Top 10 Hldgs %
68.84%
Holding
41
New
15
Increased
5
Reduced
9
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$45.2M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$26.9M |
| 3 |
Arcutis Biotherapeutics
ARQT
|
+$25.4M |
| 4 |
Relmada Therapeutics
RLMD
|
+$23.1M |
| 5 |
Xenon Pharmaceuticals
XENE
|
+$20.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$43.2M |
| 2 |
Vaxcyte
PCVX
|
+$37.5M |
| 3 |
TERN
Terns Pharmaceuticals
TERN
|
+$27.5M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
+$24.4M |
| 5 |
Enliven Therapeutics
ELVN
|
+$23.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
BioMarin Pharmaceuticals
BMRN
$12.9B
| $81.9M | 17.42% |
1,431,590
+163,200
| +13% | +$8.94M |
|
|
2
Gilead Sciences
GILD
$181B
| $43.3M | 9.21% |
+343,043
| New | +$45.2M |
|
|
3
Arcutis Biotherapeutics
ARQT
$3.15B
| $28.6M | 6.07% |
+1,089,701
| New | +$25.4M |
|
|
4
Madrigal Pharmaceuticals
MDGL
$11.9B
| $28.2M | 6% |
+52,545
| New | +$26.9M |
|
|
BCAX
5
Bicara Therapeutics
BCAX
$1.58B
| $26.5M | 5.63% |
892,621
-367,515
| -29% | -$8.2M |
|
|
6
Relmada Therapeutics
RLMD
$494M
| $25.3M | 5.38% |
3,655,075
+3,312,323
| +966% | +$23.1M |
|
7
Trevi Therapeutics
TRVI
$2.56B
| $25M | 5.31% |
1,339,212
+969,037
| +262% | +$14.1M |
|
8
Pharvaris
PHVS
$2.55B
| $23.4M | 4.98% |
677,879
+510,865
| +306% | +$15.5M |
|
|
9
Xenon Pharmaceuticals
XENE
$5.88B
| $22.2M | 4.72% |
+367,900
| New | +$20.4M |
|
10
ANI Pharmaceuticals
ANIP
$1.73B
| $19.4M | 4.11% |
233,808
-84,783
| -27% | -$6.8M |
|
11
Immunocore
IMCR
$1.9B
| $16.3M | 3.46% |
+512,856
| New | +$15.2M |
|
12
Amylyx Pharmaceuticals
AMLX
$4.31B
| $16.1M | 3.41% |
894,058
-704,736
| -44% | -$10.9M |
|
13
Insmed
INSM
$27.5B
| $13M | 2.77% |
+122,375
| New | +$14.8M |
|
|
NUVL
14
DELISTED
Nuvalent
NUVL
| $12.2M | 2.58% |
98,442
-202,388
| -67% | -$21.8M |
|
15
Capricor Therapeutics
CAPR
$366M
| $10.1M | 2.15% |
420,751
-488,456
| -54% | -$14.8M |
|
16
Aclaris Therapeutics
ACRS
$944M
| $9.31M | 1.98% |
+1,759,492
| New | +$7.85M |
|
17
Immunic
IMUX
$225M
| $8.3M | 1.76% |
+539,814
| New | +$6.66M |
|
18
Oric Pharmaceuticals
ORIC
$1.47B
| $8.09M | 1.72% |
+747,313
| New | +$6.78M |
|
19
Tonix Pharmaceuticals
TNXP
$215M
| $7.98M | 1.7% |
625,428
+173,312
| +38% | +$2.24M |
|
20
Syndax Pharmaceuticals
SNDX
$1.75B
| $7.43M | 1.58% |
+340,000
| New | +$7.07M |
|
21
Olema Pharmaceuticals
OLMA
$935M
| $7.18M | 1.53% |
+574,166
| New | +$7.69M |
|
22
Vir Biotechnology
VIR
$1.65B
| $6.72M | 1.43% |
659,213
-539,000
| -45% | -$5.13M |
|
23
Corbus Pharmaceuticals
CRBP
$201M
| $6.13M | 1.3% |
+653,572
| New | +$6.19M |
|
24
Dianthus Therapeutics
DNTH
$6.21B
| $5.57M | 1.18% |
+57,100
| New | +$4.99M |
|
|
25
Vertex Pharmaceuticals
VRTX
$139B
| $5.53M | 1.17% |
11,123
-97,480
| -90% | -$43.2M |
|
Similar funds
AIM
BFA
ACM
HNWAG
BTWM
DBRC
DWML
CFLC
Jones Hill Capital's Q2 2026 Portfolio in Review
As of Q2 2026, Jones Hill Capital held 41 positions worth $470M, up 0.83% from $466M the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Jones Hill Capital withdrew a net $35.1M in Q2 2026, closing 12 positions and reducing 9 holdings. Its most notable exit was Vaxcyte, an estimated $37.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Jones Hill Capital opened a new position in Gilead Sciences worth $43.3M.
- Jones Hill Capital's largest Q2 2026 buy was Gilead Sciences: 343,043 shares worth $43.3M.
- Jones Hill Capital added most to Relmada Therapeutics in Q2 2026, an estimated $23.1M increase.
- Jones Hill Capital's biggest Q2 2026 reduction was Vertex Pharmaceuticals, cutting an estimated $43.2M.
- Jones Hill Capital fully exited Vaxcyte in Q2 2026, selling an estimated $37.5M.
- Jones Hill Capital's ten largest holdings make up 69% of its $470M portfolio in Q2 2026.
- Jones Hill Capital opened 15 new positions and closed 12 in Q2 2026.
- Jones Hill Capital's portfolio value rose 0.83% quarter-over-quarter to $470M.
Based on Jones Hill Capital's 13F filing for Q2 2026, filed 13 Aug 2026.